Glembatumumab (Biosimilar Reference Antibody) (GPNMB)
Glembatumumab (Biosimilar Reference Antibody) (GPNMB)
Glembatumumab (Biosimilar Reference Antibody) (GPNMB)-RA0278-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
ELISA plate pre-coated Antigen protein, can bind Glembatumumab (Biosimilar Reference Antibody) (GPNMB)-RA0278 in a linear range of 0.18–15 ng/mL.
Glembatumumab (Biosimilar Reference Antibody) (GPNMB)

Catalog: 

RA0278

Target

GPNMB

Isotype

IgG2 - kappa

Applications

ELISA;FC;Functional Assays;IF

Reactivities

Human

Size (＄)：

100 μg-50;1 mg-210;5 mg-500;10 mg-800;25 mg-1750;50 mg-3000;100 mg-4600

Data Sheet

Material Safety Data Sheet

Certificate of Analysis

Product Description

Glembatumumab vedotin (development code CDX-011) is an investigational antibody-drug conjugate (ADC) developed for the treatment of advanced breast cancer and melanoma. It is engineered by linking a fully human monoclonal antibody to a potent cytotoxic payload, monomethyl auristatin E (MMAE), via a cleavable linker. Glembatumumab vedotin functions as a targeted chemotherapy agent. The antibody component specifically binds to its target antigen, glycoprotein NMB (GPNMB), which is overexpressed on certain cancer cells. Upon binding, the ADC is internalized into the target cell, where the linker is cleaved, releasing the MMAE payload. MMAE disrupts microtubule networks, inhibits cell division, and induces apoptosis, leading to tumor cell death.

Synonyms

CDX-011 (DOX), CR011, glembatumumab vedotin (ADC)

CAS

1020264-78-1

Isotype

IgG2 - kappa

Host

Genetically human

Target

GPNMB

Reactivity

Human

Expression System

CHO

Applications

ELISA, FC, Functional Assays, IF; Recommended dilution: FC, IF:1:200

Purity

>98% by SDS-PAGE

Concentration

Bottled at the concentration indicated on the vial.

Buffer

0.01M PBS, pH 7.4, contains no stabilizers or preservatives.

Endotoxin

<1.0 EU/mg as determined by LAL method

Conjugation

Non-conjugated

Formulation

Liquid or Lyophilized powder Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

store at -20°C or -80°C. Avoid repeated freeze.

Type

Antibody

Purposes

For research use only

References 1

Naumovski L, et al. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010 Apr;12(2):248-57.

References 2

E Anders Kolb, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Oct;61(10):1816-21.

References 3

References 4

References 5

Product Citations 1

Product Citations 2

https://pubmed.ncbi.nlm.nih.gov/20373269/
https://pubmed.ncbi.nlm.nih.gov/24912408/
https://www.oursmab.com/News/The-melanogenic-enzyme-GPNMB.html

Target Description

Synonyms

glycoprotein (transmembrane) nmb, glycoprotein transmembrane NMB, glycoprotein nonmetastatic melanoma protein B, CG56972, osteoactivin, hematopoeitic growth factor inducible neurokinin-1 type, HGFIN

Biology Area

Tumor Antigens;Cancer Biology

Function

Glycoprotein NMB (GPNMB), also known as osteopontin-like protein or hematopoietic growth factor inducible neurokinin-1 type. GPNMB is a type I transmembrane glycoprotein that is overexpressed in a subset of aggressive breast cancers (particularly triple-negative breast cancer, TNBC) and melanomas, while its expression in most normal adult tissues is low. Its overexpression is associated with increased metastatic potential, invasiveness, and poor prognosis.

Additional Articles 1

The-melanogenic-enzyme-GPNMB

Additional Articles 2

Related Products

Icatolimab (Biosimilar Reference Antibody) (BTLA)

Catalog: 

RA0278

Target：

BTLA/CD272

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Emicizumab (Biosimilar Reference Antibody) (F9/Factor IX)

Catalog: 

RA0278

Target：

F9/Factor IX

Isotype：

IgG4 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Maftivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0278

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Lusvertikimab (Biosimilar Reference Antibody) (IL7R)

Catalog: 

RA0278

Target：

IL7R/CD127

Isotype：

IgG4 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Odesivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0278

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Porgaviximab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0278

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Enokizumab (Biosimilar Reference Antibody) (IL9)

Catalog: 

RA0278

Target：

IL9

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Bapotulimab (Biosimilar Reference Antibody) (ILDR2)

Catalog: 

RA0278

Target：

ILDR2

Isotype：

IgG2 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Atoltivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0278

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Tocilizumab (Biosimilar Reference Antibody) (IL6R)

Catalog: 

RA0278

Target：

IL6R/CD126

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human

Contact Us

Send your request

Talk to us 

Get a quotation, discuss your requirement, receive advises from our antibody experts without obligation.